Items Tagged ‘nsclc’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 25th, 2016

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such as Keytruda […]

View full entry

Tags: fda, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


September 14th, 2016

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug that is planned for use to treat a serious or life-threatening disease […]

View full entry

Tags: advanced, General Lung Cancer, KEYNOTE-024, Lung Cancer, Lung Cancer - Non-Small Cell, Merck, News, nsclc, pembrolizumab, Stages IIIB-IV Lung Cancer - Non-Small Cell


September 13th, 2016

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer

By

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled trial of its kind. As many as 30% of all patients with NSCLC will present with or develop brain metastases. There is currently a routine practice […]

View full entry

Tags: advanced, brain metastases, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, QUARTZ, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, surgery, WBRT


June 6th, 2016

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising for the treatment of non-small cell lung cancer (NSCLC). Based on these initial results, two comparative clinical trials have been initiated. The programmed death (PD-1) inhibitor Keytruda (pembrolizumab) […]

View full entry

Tags: fda, immunotherapy, KEYNOTE-189, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, PD-1 inhibitor, pembrolizumab


March 29th, 2016

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations

By

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment of patients with NSCLC that have a mutation in the anaplastic lymphoma kinase (ALK) gene. Lung cancer […]

View full entry

Tags: clinical trial, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, ROS-1 gene, xalkori


December 24th, 2015

Alecensa ™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer

By

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa ™ (Alectinib) is indicated for advanced, metastatic, ALK-positive NSCLC in patients unresponsive to or intolerant of another ALK inhibitor, Xalkori ™ (crizotinib). The investigative agent, Alecensa, produces high anti-cancer responses […]

View full entry

Tags: Alecensa, alectinib, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc


December 3rd, 2015

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer

By

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were recently published as a rapid online communication article in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer-related deaths in the United States. Non-small cell lung […]

View full entry

Tags: alectinib, alk, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell


November 19th, 2015

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer

By

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication specifies that patients must have non-small cell lung cancer (NSCLC) that has progressed despite treatment with other approved agents that block the EGFR pathway. The diagnostic […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, osimertinib, T790M mutation, tagrisso


November 10th, 2015

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer

By

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published in the New England Journal of Medicine while simultaneously being presented at the 2015 European Cancer Congress. Lung cancer remains […]

View full entry

Tags: advanced, docetaxel, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-squamous, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell, squamous


October 19th, 2015

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer

By

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into two main groups based upon the type of cells comprising the cancer: non-squamous and squamous cell. […]

View full entry

Tags: FDA approval, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, non-squamous, nsclc, opdivo, Stages I-IIIA Lung Cancer - Non-Small Cell


September 23rd, 2015

Iressa® Approved as Initial Therapy for Lung Cancer

By

The targeted agent Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration (FDA) as initial therapy in the treatment of patients with advanced lung cancer. Specifically, Iressa was approved as initial therapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific mutations within the EGFR pathway. The […]

View full entry

Tags: advanced lung cancer, EGFR mutations, EGFR RGQ PCR Kit, FDA approval, gefitinib, iressa, Lung Cancer - Non-Small Cell, News, nsclc, Stages IIIB-IV Lung Cancer - Non-Small Cell